Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Operations

v3.3.0.814
Condensed Consolidated Statement of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Revenue        
Medical devices $ 1,095 $ 789 $ 3,128 $ 2,006
Engineering services 1,820 799 3,590 1,841
Total revenue 2,915 1,588 6,718 3,847
Cost of revenue        
Medical devices 1,095 578 2,863 1,410
Engineering services 1,352 530 2,482 1,432
Total cost of revenue 2,447 1,108 5,345 2,842
Gross profit 468 480 1,373 1,005
Operating expenses        
Sales and marketing 2,380 1,642 6,754 5,022
Research and development 1,713 1,096 4,438 2,564
General and administrative 1,556 1,474 5,090 5,354
Total operating expenses 5,649 4,212 16,282 12,940
Loss from operations (5,181) (3,732) (14,909) (11,935)
Other income (expense)        
Interest expense $ (4) (3) $ (10) (433)
Gain (loss) on warrant liability 15,773 (1,206)
Interest income $ 2 1 $ 9 4
Other expense, net (2) (15) (35) (44)
Total other income (expense), net (4) 15,756 (36) (1,679)
Net income (loss) $ (5,185) $ 12,024 $ (14,945) $ (13,614)
Basic net income (loss) per share $ (0.05) $ 0.15 $ (0.15) $ (0.18)
Weighted-average shares used in computing basic per share amounts 102,239,868 78,513,144 102,043,392 74,943,169
Diluted net income (loss) per share $ (0.05) $ (0.04) $ (0.15) $ (0.18)
Weighted-average shares used in computing diluted per share amounts 102,239,868 83,336,371 102,043,392 74,943,169